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Compounds 3c2, 2d1, 3d1, 2f2, 3f2, and 4a4 were not able to in
duce HEXIM1 expression, at 100 lM. However, compounds 3a2
and 3d2 showed signiﬁcant activity at 100 lM that was not ob
served at 500 lM. The variation in potency could be due to the pre
cipitation of the two compounds at 500 lM, which hampers cell
penetration. Compounds 3b1 and 3b2 with the aromatic ring at
B moiety showed good activity at 100 lM, and induced HEXIM1
expression by 3.8 and 2 fold, respectively. Compounds 2a4, 2a5,
and 4a1 exhibited reduced activity at lower concentrations, sug
gesting dose dependent stimulation of HEXIM1 expression by
these compounds. Due to the unsymmetrical structural character
istics of 4a1, a dose dependent study was performed and the re
sults are presented in Figure 4. The compound dose dependently
induced HEXIM1 expression suggesting that the unsymmetrical
structure and increased hydrophobicity contribute to improved
biological activity. Considering the aromatic moiety of compounds
3b1 and 3b2 and the bulky terminal moiety of compounds 2a4 and
2a5, more potent analogs could be developed if several of these
structural units are combined in the new drug design.
In brief, our ﬁndings have provided unique molecular scaffolds
that signiﬁcantly induced HEXIM1 expression in prostate cancer
cells, and have opened a new lead optimization direction of HMBA.
To the best of our knowledge, this is the ﬁrst study focusing on the
lead optimization of HMBA to generate more potent HEXIM1
inducers. The results support the potential of unsymmetrical
HMBA derivatives as lead compounds. More potent HEXIM1 induc
ers have potential application in cancer, AIDS, and heart disease
treatment. Further lead optimization of HMBA to generate more
potent HEXIM1 inducers is currently underway in our laboratory.
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Figure 4. Dose-dependent study of compound 4a1 and HMBA on HEXIM1 expression. Level of HEXIM1 (upper panel) and b-actin (lower panel) was analyzed byWestern blot
of cell extracts with HEXIM1 antibody and b-actin, antibody respectively.
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